Robustness against serum neutralization of a poliovirus type 1 from a lethal epidemic of poliomyelitis in the Republic of Congo in 2010

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 35, 2014, Pages 12889-12894

  Drexler, Jan Felix ^a   Grard, Gilda ^b   Lukashev, Alexander N ^c   Kozlovskaya, Liubov I ^c   Boẗtcher, Sindy ^d   Uslu, Gökhan ^e   Reimerink, Johan ^e   Gmyl, Anatoly P ^c,f   Taty Taty, Raphaël ^g   Lekana Douki, Sonia Etenna ^b   Nkoghe, Dieudonné ^b   Eis Hübinger, Anna M ^a   Diedrich, Sabine ^d   Koopmans, Marion ^e   Leroy, Eric M ^b,h   Drosten, Christian ^a  

^a UNIVERSITY OF BONN   (Germany)

^b CENTRE INTERNATIONAL DE RECHERCHES MÉDICALES DE FRANCEVILLE   (Gabon)

^c CHUMAKOV INSTITUTE OF POLIOMYELITIS AND VIRAL ENCEPHALITIDES   (Russian Federation)

^d ROBERT KOCH INSTITUTE   (Germany)

^e Netherlands Center for Infectious Disease Control   (Netherlands)

^f MOSCOW STATE UNIVERSITY   (Russian Federation)

^g Ministry of Health   (Congo)

^h CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, NEUTRALIZING; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CHILD; CONGO; EPIDEMICS; GENOME, VIRAL; HUMANS; MASS VACCINATION; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHYLOGENY; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; RHABDOMYOSARCOMA; VERO CELLS; VIRULENCE; YOUNG ADULT;

EID: 84907228045     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1323502111     Document Type: Article

References (41)

1. Nathanson N, Kew OM (2010) From emergence to eradication: The epidemiology of poliomyelitis deconstructed. Am J Epidemiol 172(11):1213-1229.
2. Centers for Disease Control and Prevention (CDC) (2011) Progress toward interrupting wild poliovirus circulation in countries with reestablished transmission - Africa, 2009-2010. MMWR Morb Mortal Wkly Rep 60(10):306-311.
3. Patriarca PA (2012) Research and development and the polio eradication initiative: Too much, too soon...too little, too late? Clin Infect Dis 55(10):1307-1311.
4. The Global Polio Eradication Initiative (2014) Wild Poliovirus (WPV) cases. Available at www.polioeradication.org/Dataandmonitoring/Poliothisweek. aspx. Accessed May 21, 2014.
5. Patel MK, et al. (2012) An outbreak of wild poliovirus in the Republic of Congo, 2010-2011. Clin Infect Dis 55(10):1291-1298.
6. Yakovenko ML, et al. (2014) The 2010 outbreak of poliomyelitis in Tajikistan: Epidemiology and lessons learnt. Euro Surveill 19(7):20706.
7. Luo HM, et al. (2013) Identification and control of a poliomyelitis outbreak in Xinjiang, China. N Engl J Med 369(21):1981-1990.
8. Centers for Disease Control and Prevention (CDC) (2011) Poliomyelitis outbreak - Republic of the Congo, September 2010-February 2011. MMWR Morb Mortal Wkly Rep 60(10):312-313.
9. Roberts L (2010) Infectious disease. Polio outbreak breaks the rules. Science 330(6012):1730-1731.
10. Grard G, et al. (2010) Type 1 wild poliovirus and putative enterovirus 109 in an outbreak of acute flaccid paralysis in Congo, October-November 2010. Euro Surveill 15(47):19723.
11. Le Menach A, et al. (2011) Poliomyelitis outbreak, Pointe-Noire, Republic of the Congo, September 2010-February 2011. Emerg Infect Dis 17(8):1506-1509.
12. Crawford CL (2011) No mystery about the polio outbreak. Science 331(6018):674.
13. World Health Organization (2014) Acute flaccid paralysis (AFP) surveillance data. http://apps.who.int/immunization-monitoring/en/diseases/ poliomyelitis/case-count.cfm. Accessed May 30, 2014.
14. Pallansch MA, Roos RP (2001) Enteroviruses: Polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. Fields Virology, eds Knipe DM, Howley PM (Lippincott-Raven, Philadelphia), 4th Ed, Vol 1, pp 724-743.
15. Diedrich S, Claus H, Schreier E (2002) Immunity status against poliomyelitis in Germany: determination of cut-off values in International Units. BMC Infect Dis 2:2.
16. Osterhaus AD, et al. (1983) Monoclonal antibodies to polioviruses. Comparison of intratypic strain differentiation of poliovirus type 1 using monoclonal antibodies versus cross-absorbed antisera. Intervirology 20(2-3):129-136.
17. Minor PD, Ferguson M, Evans DM, Almond JW, Icenogle JP (1986) Antigenic structure of polioviruses of serotypes 1, 2 and 3. J Gen Virol 67(Pt 7):1283-1291.
18. Herremans MM, et al. (1997) Evaluation of a poliovirus-binding inhibition assay as an alternative to the virus neutralization test. Clin Diagn Lab Immunol 4(6):659-664.
19. Korotkova EA, et al. (2003) Retrospective analysis of a local cessation of vaccination against poliomyelitis: A possible scenario for the future. J Virol 77(23):12460-12465.
20. Cherkasova EA, et al. (2002) Long-term circulation of vaccine-derived poliovirus that causes paralytic disease. J Virol 76(13):6791-6799.
21. Kew O (2012) Reaching the last one per cent: Progress and challenges in global polio eradication. Curr Opinion Virol 2(2):188-198.
22. Sabin AB (1952) Transitory appearance of type 2 neutralizing antibody in patients infected with type 1 poliomyelitis virus. J Exp Med 96(1):99-106.
23. Danes L, Sladká E, Hancil J, Horácek J (1988) Cross reactivity among human enterovirus serotypes as revealed by microneutralization assay technique. J Hyg Epidemiol Microbiol Immunol 32(2):233-238.
24. Uytdehaag FG, et al. (1985) Human peripheral blood lymphocytes from recently vaccinated individuals produce both type-specific and intertypic cross-reacting neutralizing antibody on in vitro stimulation with one type of poliovirus. J Immunol 135(5):3094-3101.
25. Centers for Disease Control and Prevention (CDC) (2011) Progress toward interruption of wild poliovirus transmission - worldwide, January 2010-March 2011. MMWR Morb Mortal Wkly Rep 60(18):582-586.
26. Wassilak S, et al. (2011) Outbreak of type 2 vaccine-derived poliovirus in Nigeria: Emergence and widespread circulation in an underimmunized population. J Infect Dis 203(7):898-909.
27. Minor PD (2012) The polio-eradication programme and issues of the end game. J Gen Virol 93(Pt 3):457-474.
28. Gregory CJ, et al. (2012) Investigation of elevated case-fatality rate in poliomyelitis outbreak in Pointe Noire, Republic of Congo, 2010. Clin Infect Dis 55(10):1299-1306.
29. Prevots DR, et al. (1998) Outbreak of paralytic poliomyelitis in Albania, 1996: High attack rate among adults and apparent interruption of transmission following nationwide mass vaccination. Clin Infect Dis 26(2):419-425.
30. Minor PD (1990) Antigenic structure of picornaviruses. Curr Top Microbiol Immunol 161:121-154.
31. Page GS, et al. (1988) Three-dimensional structure of poliovirus serotype 1 neutralizing determinants. J Virol 62(5):1781-1794.
32. Rezapkin G, et al. (2010) Repertoire of antibodies against type 1 poliovirus in human sera. J Virol Methods 169(2):322-331.
33. Reinheimer C, Friedrichs I, Rabenau HF, Doerr HW (2012) Deficiency of immunity to poliovirus type 3: A lurking danger? BMC Infect Dis 12:24.
34. Peart AF, et al. (1949) An outbreak of poliomyelitis in Canadian Eskimos in wintertime. Can J Public Health 40(10):405-419.
35. Hovi T, et al. (1986) Outbreak of paralytic poliomyelitis in Finland: Widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population. Lancet 1(8495):1427-1432.
36. Huovilainen A, Kinnunen L, Ferguson M, Hovi T (1988) Antigenic variation among 173 strains of type 3 poliovirus isolated in Finland during the 1984 to 1985 outbreak. J Gen Virol 69(Pt 8):1941-1948.
37. Huovilainen A, et al. (1987) Evolution of poliovirus during an outbreak: Sequential type 3 poliovirus isolates from several persons show shifts of neutralization determinants. J Gen Virol 68(Pt 5):1373-1378.
38. Hovi T, Lindholm N, Savolainen C, Stenvik M, Burns C (2004) Evolution of wild-type 1 poliovirus in two healthy siblings excreting the virus over a period of 6 months. J Gen Virol 85(Pt 2):369-377.
39. Shulman LM, et al. (2000) Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel. J Clin Microbiol 38(10):3729-3734.
40. Morrison EG, Embil JA (1987) Poliomyelitis in North America: The disease is not dead yet. CMAJ 137(12):1085-1087.
41. Ehrenfeld E, Modlin J, Chumakov K (2009) Future of polio vaccines. Expert Rev Vaccines 8(7):899-905.